SAN LUIS OBISPO, California – March 22, 2007 – FzioMed, Inc. announced today that a review of the company’s research on novel, synthetic dermal fillers is being presented at the Anti-Aging Medical World Congress (AAMWC) in Monte Carlo March 22-24, 2007.
In 2006, FzioMed launched Laresse Dermal Filler, the first ultra-smooth, non-permanent, synthetic filler created from the company’s patented polymer science. Laresse represents a completely new class of filler for the correction of wrinkles and lines caused by sun exposure, aging and other factors.
After extensive characterization of cross-linked hyaluronic acid (HA) fillers, FzioMed designed Laresse from biocompatible polymers to have key gel properties that offer significant advantages over common fillers being used today. For example, Laresse is stable without chemical cross-linking, completely free of both bacterial and animal by-products, and smoother and easier to inject than HA fillers.
Richard Berg, Ph.D., FzioMed’s Chief Scientific Officer, will present “Novel Synthetic Dermal Fillers” at AAMWC on March 24th. His talk will describe the rheological properties of commercialized cross-linked HA fillers and includes data demonstrating the broader versatility and advantages of FzioMed’s polymer technology for formulating a family of improved dermal fillers, including Laresse.
“This presentation highlights FzioMed’s approach of applying science to the rapidly evolving field of soft tissue augmentation,” said John Krelle, FzioMed President & Chief Executive Officer.
Laresse Dermal Filler is an ultra-smooth, non-permanent, non-HA gel composed of pure, absorbable medical polymers. Laresse is the first non-permanent filler without many of the drawbacks of HA and collagen fillers. No other filler offers the same features as Laresse: non-permanent wrinkle correction, non-animal and non-bacterial components, easy injection through a very fine needle, and ultra-smooth texture and feel. Laresse is currently available only in the European Union.
FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company’s patented science. FzioMed’s polymer technology has uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the U.S., Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse dermal filler. FzioMed products are for investigational use only in the U.S.
FzioMed®, Oxiplex® and Laresse® are registered trademarks of FzioMed, Inc.